Los Angeles-based Cedars-Sinai has deployed OpenEvidence systemwide, giving clinicians access to patient-specific medical literature within its EHR.
The clinical reference tool links peer-reviewed evidence to patient data — including prior procedures, medications, allergies and comorbidities — to support diagnosis and treatment decisions. Cedars-Sinai also plans to integrate its own care pathways and protocols into the platform, according to a May 20 news release.
The integration gives clinicians “a more complete and actionable understanding at the moment of care,” Cedars-Sinai Chief Health Informatics Officer Shaun Miller, MD, said in the release.
The deal follows a similar partnership announced March 31 between OpenEvidence and New York City-based Mount Sinai Health System, which the AI company described as its first enterprise deal with a health system.
OpenEvidence raised $250 million at a $12 billion valuation in January, up from $1 billion just over a year prior. The platform, which is free for physicians and trained solely on medical journals and data, says it was used by roughly 65% of U.S. physicians across nearly 27 million clinical encounters in April, according to NBC News.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
